etentamig + lenalidomide + dexamethasone

This is a combination therapy consisting of **etentamig**, **lenalidomide**, and **dexamethasone**. - **Etentamig** (also known as ABBV-383, TNB-383B) is an investigational **bispecific antibody** that targets both **B-cell maturation antigen (BCMA)** found on multiple myeloma cells and **CD3** on T cells, thereby redirecting T-cell cytotoxicity specifically toward myeloma cells. - **Lenalidomide** is an immunomodulatory agent commonly used in multiple myeloma for its anti-angiogenic, antineoplastic, and immunostimulatory effects, including modulation of cytokine production and enhancement of T and NK cell activity. - **Dexamethasone** is a synthetic corticosteroid that exerts anti-inflammatory and cytotoxic effects, often used in combination regimens for multiple myeloma to augment anti-tumor activity and reduce some treatment-related inflammation. This investigational combination is being evaluated in clinical studies for the treatment of **relapsed/refractory multiple myeloma**[8][1][3].